Savara (SVRA) Interest & Investment Income (2010 - 2026)
Savara (SVRA) reported Interest & Investment Income of $1.1 million for Q1 2026, down 29.44% year-over-year from $1.5 million in Q1 2025, and down 11.55% quarter-over-quarter from $1.2 million in Q4 2025.
Savara (SVRA) Interest & Investment Income (2010 - 2026) Analysis & Trends
Savara (SVRA) has 17 years of Interest & Investment Income data on file, last reported at $1.1 million in Q1 2026.
- Interest & Investment Income for Q1 2026 came in at $1.1 million, down 29.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.7 million (down 43.72% YoY), and the FY2025 annual result was $4.2 million, down 35.64% from the prior year.
- Interest & Investment Income declined to $1.1 million in Q1 2026 per SVRA's latest filing, from $1.2 million in the prior quarter.
- Over five years, Interest & Investment Income peaked at $2.1 million in Q3 2024 and troughed at -$570000.0 in Q1 2022.
- A 5-year average of $943235.3 and a median of $1.1 million in 2026 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2023 and 2025: Interest & Investment Income soared 850.0% in 2023, then tumbled 74.26% in 2025.
- A 5-year view of Interest & Investment Income shows it stood at $614000.0 in 2022, then soared by 147.39% to $1.5 million in 2023, then advanced by 25.94% to $1.9 million in 2024, then slumped by 37.53% to $1.2 million in 2025, then dropped by 11.55% to $1.1 million in 2026.
- Business Quant data shows SVRA's Interest & Investment Income at $1.1 million in Q1 2026, $1.2 million in Q4 2025, and $548000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 597,319.59 |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 40.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 103,341.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 114.80 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -14.79 Mn |
| 10 | Savara | 1.33 Bn | 1.33 Bn | - | 1.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.06 Mn |
| Dec 31, 2025 | 1.20 Mn |
| Sep 30, 2025 | 548,000.00 |
| Jun 30, 2025 | 921,000.00 |
| Mar 31, 2025 | 1.50 Mn |
| Dec 31, 2024 | 1.91 Mn |
| Sep 30, 2024 | 2.13 Mn |
| Jun 30, 2024 | 1.07 Mn |
| Mar 31, 2024 | 1.35 Mn |
| Dec 31, 2023 | 1.52 Mn |
| Sep 30, 2023 | 1.44 Mn |
| Jun 30, 2023 | 709,000.00 |
| Mar 31, 2023 | 765,000.00 |
| Dec 31, 2022 | 614,000.00 |
| Sep 30, 2022 | 152,000.00 |
| Jun 30, 2022 | -284,000.00 |
| Mar 31, 2022 | -570,000.00 |
| Dec 31, 2021 | -565,000.00 |
| Sep 30, 2021 | -566,000.00 |
| Jun 30, 2021 | -558,000.00 |